Biopharma M&A Heats Up, Rare Diseases Win Three Approvals, Wave Crashes
Biopharma giants Biogen, Eli Lilly and Merck collectively spent over $20 billion in a single week to acquire biotech firms with approved products or promising pipelines, accounting for three of the year’s four largest deals. Merck bought Terns Pharmaceuticals for $6.7 billion, while Lilly and Biogen each secured Centessa and Apellis in separate $2 billion‑plus transactions. The FDA also approved three new rare‑disease therapies, highlighting continued momentum in that niche. Meanwhile, Wave Life Sciences saw its stock halve after a disappointing Phase 1 obesity trial.
Ambrosia Eyes Next-Generation Small Molecule GLP-1s With $100M Series B
Ambrosia Biosciences announced the completion of a $100 million Series B financing round to fund the development of next‑generation small‑molecule GLP‑1 oral therapies for obesity. The capital will support a Phase 1 trial of its lead GLP‑1 candidate, which leverages AI‑driven molecular design...
Rare Disease Advocacy Group Urges Trump Administration to Restore FDA Clarity
A coalition of nearly 100 rare‑disease patient groups, biotech executives and investors wrote to President Trump, Health Secretary Robert F. Kennedy Jr., Medicare administrator Mehmet Oz and FDA Commissioner Marty Makary urging the administration to restore regulatory clarity at the...
Smart Drugs Are Here
A recent proof‑of‑concept study introduces DNA‑drug conjugates (DDCs) that turn “smart drugs” into programmable therapies. DDCs use split DNA strands as logic gates to release payloads only when specific biomarker combinations are present, offering higher specificity than antibody‑drug conjugates (ADCs)....
Axsome Therapeutics Acquires Global Rights to Balipodect From Takeda
Axsome Therapeutics has signed an asset purchase agreement with Takeda to acquire worldwide rights to the PDE10A inhibitor TAK‑063, branded as balipodect. The deal provides Axsome with the ability to develop, manufacture and commercialize the drug for schizophrenia and Tourette...
Protective Effects of Gypenosides on LDL-Induced Myocardial Injury Through the miR-223/NLRP3 Axis in Hyperlipidemia
A cross‑sectional analysis of 19,862 Chinese adults linked elevated LDL‑C to higher glucose, BMI, blood pressure, white‑blood‑cell count and triglycerides, especially among middle‑aged and older men. Parallel in‑vitro experiments showed native LDL directly impairs H9C2 cardiomyocyte viability, proliferation, migration and...
Estonian Validfor Raises $1.2 Mililion Pre-Seed to Cut Pharma Validation Timelines From Months to Weeks
Estonian compliance startup Validfor secured a $1.2 million pre‑seed round led by DOMiNO Ventures, with participation from Curiosity VC and angels. The company is building an AI‑native, agentic digital validation platform that promises to shrink pharma, biotech and medtech validation cycles...
IO Shuts Down Following Regulatory Roadblocks
Danish biotech IO Biotech announced it will wind down operations and file for Chapter 7 bankruptcy after regulatory setbacks. The FDA rejected its biologics license application for the cancer vaccine Cylembio in September, citing insufficient data. A Phase 3 trial combining Cylembio...
EMA Seeks Input on Virtual Alternative to Animal Test
The European Medicines Agency has released a draft qualification opinion that would allow virtual control groups (VCGs) to replace rats in dose‑range‑finding toxicology studies. The proposal, submitted by Synapse Research and five pharma partners under the VICT3R consortium, is open...
Metformin Undermines Exercise’s Insulin‑Sensitivity Gains
As a medical school professor, I've recommended metformin to countless patients. But a new double-blind trial just revealed something alarming. Metformin BLUNTED the insulin-sensitizing benefits of exercise in adults at risk for metabolic syndrome. The findings from a 16-week RCT: -> Exercise +...
Medical Podcasts
Medical Design Briefs released a series of podcasts on April 1 2026 highlighting emerging trends in drug delivery. The episodes cover AI‑driven personalized medicine in oncology, sustainability challenges for insulin pens and other devices, intra‑arterial platforms that target solid tumors, and wearable...
Medical Podcasts
Medical Design Briefs released a series of April 2026 podcasts spotlighting emerging drug‑delivery trends. Episodes feature First Ascent Biomedical’s AI‑driven platform that personalizes oncology therapy, MGS engineers discussing greener insulin‑pen designs, RenovoRx’s intra‑arterial delivery system that targets solid tumors, and...
Clinical Trial For Brain Cancer Treatment Has Promising Results
A novel glioblastoma treatment combining oral 5‑ALA with low‑intensity ultrasound has shown promising early results, extending median survival by over 14 months in a phase 1 trial for recurrent patients. The approach sensitizes tumor cells to ultrasound, allowing diffuse targeting of...
Sweat-Powered Sticker Turns Drinking Cup Into a Health Sensor
UC San Diego engineers have created a battery‑free electronic sticker that attaches to drinking cups and measures a user’s vitamin C levels from fingertip sweat. The biofuel cell harvests sweat‑derived electricity to power a hydrogel‑based sensor, which wirelessly sends results to...
FDA, After Turbulent Year, Leaves Drugmakers Guessing on Its Direction
The FDA’s leadership turmoil has intensified under Commissioner Marty Makary, with the agency cycling through multiple heads of its CDER and CBER centers in just over a year. Public‑facing comments from senior officials have sparked sharp stock moves, most notably...
AI-Generated Sensors Open New Paths for Early Cancer Detection
MIT and Microsoft researchers unveiled CleaveNet, an AI system that designs peptide sensors targeting cancer‑linked proteases. The model rapidly generates highly specific sequences, cutting the design time from months to minutes and slashing experimental costs. Coated nanoparticles release cleaved peptides...
Engineers Create Hydrogels to Monitor Activity in the Body
Engineers at Washington University in St. Louis have developed granular bioelectronic hydrogels composed of PEDOT:PSS microparticles that can be injected, 3D‑printed, or spread over tissue. The material behaves like a liquid under force but solidifies into a porous, paste‑like matrix,...
Sensor Technology Detects Life-Threatening Complications After Intestinal Surgery
Researchers at TU Dresden and Rostock University Hospital have created a fully absorbable, implantable sensor film that can be sewn into intestinal anastomoses during surgery. The device continuously measures tissue impedance and temperature, delivering real‑time alerts when circulatory disorders emerge....
Will Pfizer’s Lyme Disease Gamble Pay Off or Set the Space Back?
Pfizer and French partner Valneva are seeking FDA approval for a 6‑valent OspA Lyme disease vaccine after a late‑stage trial showed more than 70% efficacy, though the study missed its primary statistical endpoint due to low infection rates. The candidate...
How Drug Discovery Is Tackling Global Health Challenges
In this DDW podcast episode, host Bruno Quinney discusses two recent DDW articles: one on the urgent need to combat antimicrobial resistance (AMR) with insights from Professor Janet Hemingway, and another on the rapid expansion of mRNA therapeutics. Hemingway highlights...
Advocating Bills to Expand Right‑to‑Try for Severe Illnesses
Today @theA4LI is at the New Hampshire State House supporting HB 1734 and HB 1735, two bills that would license experimental treatment centers and expand Right to Try protections to patients with severe illness, not just terminal conditions. As a longevity...
GSK Reports the NMPA Approval of Exdensur (Depemokimab) for Severe Asthma
GlaxoSmithKline’s biologic Exdensur (depemokimab) received approval from China’s National Medical Products Administration as an add‑on maintenance therapy for patients aged 12 and older with severe eosinophilic asthma. The approval is based on Phase III SWIFT‑1 (382 participants) and SWIFT‑2 (380 participants)...
AI Clarifies Biotech Limits, Guiding Focused Breakthroughs
“AI will not make all biology predictable. What it will do is make clearer predictions — where prediction is possible — and identify where it is not. This distinction matters because it is likely that the next decade of biotechnology...
FDA Grants RMAT Status to Caribou’s Anti‑BCMA CAR‑T Therapy
1/🚨@CaribouBio announced that the U.S. FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation to CB-011 - $CRBU allogeneic anti-BCMA CAR-T Cell Therapy for treating relapsed or refractory multiple myeloma (r/r MM) cancer which is being evaluated in the CaMMouflage...
The Biotech Bi-Weekly: Cell Barcoding, Compound Optimization and the Trillion Cell Atlas
The biotech sector is witnessing a wave of collaborations and product launches aimed at accelerating drug discovery and expanding genomic knowledge. Biotium introduced the ViaPlex™ 2‑Color Cell Barcoding Kit, enabling multiplex analysis of up to 15 cell populations in a...
Paragon Launches Korsana Biosciences, Targeting Alzheimer's
Paragon launched its 7th company today -- Korsana Biosciences, merging into the $CYCN public shell. New ticker will be $KRSA. Lead drug candidate is a shuttled anti-amyloid beta antibody for Alzheimer's disease in early studies. https://t.co/RcJ8adMakm
Oric to Advance Prostate Cancer Drug to Phase 3, but Combo Choice Raises Doubts
Oric Pharmaceuticals announced that its PRC2 inhibitor will move into a registrational Phase 3 trial for prostate cancer after reporting encouraging safety and disease‑control signals in a Phase 1b study. The company plans to evaluate the drug both as a...
Smart IUD Could ‘Provide Insights We’ve Never Had Before’
Verso Biosense, based in Oxfordshire, is creating a wireless smart IUD that continuously records uterine temperature and oxygen levels. The device aims to generate real‑time data to help clinicians understand why some IVF cycles fail and to identify conditions that...
Vertical AI Delivers Results; General AI Still Limited
Eli Lilly bet $2.75B on AI drug discovery. Best AI model in the world: 0.37% on a reasoning benchmark. Both facts are true simultaneously. Vertical AI that knows your domain: already working. General AI that reasons universally: still finding its ceiling. https://t.co/7iTOUGavT3
Frontier Medicines Grants Ex-China Rights of FMC-220 to LG Chem
Frontier Medicines has granted LG Chem an exclusive global license to develop and commercialize its covalent p53 Y220C activator FMC-220 outside Greater China, while retaining full rights within that region. LG Chem will manage regulatory filings, global clinical development, and...
MyGevity Unveils DNA‑Linked Real‑Time Lab Platform for At‑Home Longevity Testing
MyGevity announced the nationwide launch of a precision‑health platform that links at‑home genetic testing to real‑time lab diagnostics through Quest Diagnostics. The service combines DNA analysis, epigenetic age scoring and continuous biomarker monitoring, delivering personalized recommendations and a dedicated genomics...
Remaining Challenges in the Development of Partial Reprogramming Therapies
Partial reprogramming—brief exposure to Yamanaka factors OCT4, SOX2, KLF4 and MYC—has demonstrated modest rejuvenation in mouse studies but carries a substantial cancer risk if cells slip into full pluripotency. Funding is concentrated in a few well‑capitalized firms, notably Altos Labs,...
FDA Grants Accelerated Approval to Denali's Avlayah, First New Hunter Syndrome Therapy in 20 Years
The U.S. Food and Drug Administration granted accelerated approval to Denali Therapeutics' intravenous enzyme replacement therapy Avlayah, marking the first new treatment for Hunter syndrome in two decades. The approval could extend lives and curb cognitive decline for the roughly...
Rhythm Pharmaceuticals Stock Jumps 12.6% After FDA Expands Imcivree Label
Rhythm Pharmaceuticals saw its shares rise 12.58% after the FDA approved Imcivree for acquired hypothalamic obesity, expanding the drug’s addressable U.S. market by 10,000 patients. The move follows a 46% revenue jump to $189.8 million in 2025 but comes amid recent...
Hugel Taps Hans Biomed to Sell CellREDM Injectable, Expanding B2B Aesthetic Portfolio
Hugel Inc. signed a distribution deal with Hans Biomed to sell the ECM‑based injectable CellREDM™ in South Korea, marking the company's first partnership on a third‑party product and a push to broaden its B2B aesthetic offerings.
Patients Know Best and Heartfelt Technologies Collaborate to Accelerate Clinical Trial Recruitment
Patients Know Best teamed with Heartfelt Technologies to automate recruitment for the Innovate UK‑funded HF‑TRACK trial, enrolling 16 participants in just four weeks—a 135% increase over the trial’s average rate. The partnership leveraged PKB’s coded health‑record data to display a...
Ultragenyx (RARE) Shares Positive Results From DTX301 Phase 3 Study
Ultragenyx Pharmaceutical reported that its Phase 3 Enh3ance trial of DTX301, an AAV8 gene therapy for ornithine transcarbamylase deficiency, achieved an 18% reduction in 24‑hour plasma ammonia versus placebo at Week 36, with average ammonia levels staying within normal range. Eight of...
Soleno Therapeutics (SLNO) Still Appears Attractive Despite Slower U.S. Launch Ramp Projections
Oppenheimer kept an Outperform rating on Soleno Therapeutics but lowered its price target to $80 from $110, signaling a potential upside of more than 166%. Wells Fargo trimmed its target slightly to $110 while remaining Overweight. Both firms highlighted a slower‑than‑expected...
Mineralys Therapeutics (MLYS) Garnering Attention With Lorundrostat Progress
Mineralys Therapeutics (NASDAQ:MLYS) received a renewed Buy rating from Bank of America Securities, which lifted its price target to $51 from $46 after the company reported fourth‑quarter results. The firm highlighted progress on lorundrostat, an aldosterone synthase inhibitor, noting the...
Productivity Enhancing Bioreactor for Scalable Organoid Culture
AMSBIO introduced RPMotion, a spinning organoid bioreactor that accelerates and automates 3‑D cell culture for drug discovery, disease modeling and regenerative medicine. The system delivers up to five‑fold faster organoid expansion while cutting reagent costs by roughly 60% and labor...
Yes, GLP-1s Are Changing What Food People Buy — Here's How
GLP‑1 drugs such as Ozempic and Wegovy are prompting measurable changes in grocery purchasing patterns. A Danish study of 1,177 adults, covering nearly two million transactions, found that users bought foods with slightly lower calories, sugar, carbohydrates and saturated fat,...
ACC 2026: Sotatercept Shows Signal in CpcPH-HFpEF at Lower Dose
At the 2026 ACC Scientific Session, the phase‑II CADENCE trial showed that sotatercept (WINREVAIR) reduced pulmonary vascular resistance in adults with combined post‑ and precapillary pulmonary hypertension linked to HFpEF (CpcPH‑HFpEF). The study randomized 164 patients, median age 75, to...
Six Biotech Companies in Berlin to Watch in 2026
Berlin’s biotech sector is gaining global traction, highlighted by six innovative firms. 3B Pharmaceuticals secured a Novartis licensing deal for its FAP‑2286 radioligand and is collaborating on an astatine‑211 candidate. Ariceum Therapeutics dosed its first patient in a phase 1/2 trial...
Conductive Hydrogel Can Sense Oxygen and Guide Cell Behaviour
Researchers have created a conductive hydrogel, PEDOT:sGAGh, that mimics the extracellular matrix while sensing oxygen and electrically regulating growth‑factor release. By polymerizing less than 1 wt % PEDOT within a sulfated glycosaminoglycan hydrogel, they achieved a 95 wt % water‑rich, soft material with dual...
Symeres and Ambagon Collaborate for Colorectal Cancer Molecules
Symeres has partnered with Ambagon Therapeutics to evaluate molecular‑glue compounds for colorectal cancer. The collaboration will leverage Symeres’ in‑vitro assays, surface‑plasmon resonance kinetics, and fluorescence microscopy to characterize ternary‑complex formation and downstream pathway effects. Symeres will also profile each candidate...
Symeres and Ambagon Collaborate for Colorectal Cancer Molecules
Symeres has partnered with Ambagon Therapeutics to evaluate Ambagon’s molecular glue candidates for colorectal cancer. The collaboration will use Symeres’ in‑vitro assays, surface plasmon resonance, fluorescence microscopy and a 102‑cell line panel to characterize ternary complex kinetics and downstream pathway...
Boston Scientific Receives FDA Clearance for the Asurys Fluid Management System
Boston Scientific announced FDA 510(k) clearance for its Asurys Fluid Management System, a device that provides automated irrigation and intrarenal pressure control during endoscopic urologic procedures such as ureteroscopy. The system integrates with the LithoVue Elite single‑use digital ureteroscope, allowing...
STAT+: The Biotech Scorecard for the Second Quarter: 23 Stock-Moving Events to Watch
STAT’s quarterly biotech scorecard lists 23 upcoming events that could move biotech stocks in Q2 2026. Highlights include Phase 3 results from Abivax’s obefazimod in ulcerative colitis and Allogene Therapeutics’ interim data on its cema‑cel CAR‑T therapy for B‑cell lymphoma. The...
Lilly Moves Deeper Into Sleep Medicine with up to $7.8 Billion Centessa Deal
Eli Lilly announced a definitive agreement to acquire UK‑based Centessa Pharmaceuticals for up to $7.8 billion, paying $38 per share in cash and up to $9 per share in contingent milestones. The acquisition gives Lilly control of Centessa’s orexin‑receptor‑2 agonist pipeline,...
Anavex Updates Regulatory Strategy for Blarcamesine
Anavex Life Sciences has withdrawn its European Union marketing authorization application for blarcamesine and will collect additional data while maintaining dialogue with the European Medicines Agency. The company has concurrently submitted new data to the U.S. FDA to explore a...